Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance

1995 ◽  
Vol 10 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Stephen T. Gancher ◽  
John G. Nutt ◽  
William R. Woodward
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Utility

scholarly journals Clinical Utility of Skin Biopsy in Differentiating between Parkinson’s Disease and Multiple System Atrophy

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Rie Haga ◽  
Kazuhiro Sugimoto ◽  
Haruo Nishijima ◽  
Yasuo Miki ◽  
Chieko Suzuki ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Chest Wall ◽  
Clinical Utility ◽  
Nerve Fibers ◽  
The Body ◽  
Histopathological Analysis ◽  
Fiber Density ◽  
Intraepidermal Nerve Fiber Density

Background. It is often difficult to differentiate Parkinson’s disease (PD) from multiple system atrophy (MSA), especially in their early stages.Objectives. To examine the clinical utility of histopathological analysis of biopsied skin from the chest wall and/or leg in differentiating between the two diseases.Methods. Skin biopsies from the lower leg and/or anterior chest wall were obtained from 38 patients with idiopathic PD (26 treated with levodopa and 12 levodopa-naïve) and 13 age-matched patients with MSA. We sought aggregates of phosphorylatedα-synuclein on cutaneous nerve fibers using double fluorescence immunohistochemistry and confocal microscopy and measured intraepidermal nerve fiber density (IENFD).Results. Phosphorylatedα-synuclein aggregates were identified on cutaneous nerves in two patients with PD (5.3%) but in none of the patients with MSA, and IENFD was significantly lower in patients with PD when compared to those with MSA. There was no difference in IENFD between levodopa-treated and levodopa-naïve patients with PD.Conclusions. Our findings suggest that an assessment of IENFD in biopsied skin could be a useful means of differentiating between PD and MSA but that detection ofα-synuclein aggregates on cutaneous nerves in the distal sites of the body is insufficiently sensitive.

Clinical utility of visualisation of nigrosome-1 in patients with Parkinson’s disease

2017 ◽  
Vol 28 (2) ◽  
pp. 718-726 ◽  
Author(s):  
Albert Stezin ◽  
Rajini M. Naduthota ◽  
Ragasudha Botta ◽  
Shriram Varadharajan ◽  
Abhishek Lenka ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Utility

From GWAS to clinical utility in Parkinson's disease

The Lancet ◽  
2011 ◽  
Vol 377 (9766) ◽  
pp. 613-614 ◽  
Author(s):  
Christine Klein ◽  
Andreas Ziegler
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Utility
Sign in / Sign up

Export Citation Format

Share Document